The Democratic primary opponent of Rep. Thaddeus Jones (D- Calumet City) recently ripped into the incumbent for his position on a bill last year to create a new state board that would have the power to cap some prescription drug prices.
"Thaddeus Jones voted against lowering the cost of prescription drugs," the DeAndre Tillman mailer proclaims. "All the while pocketing thousands of dollars." The claim is printed just above an image of two shaking hands, a bunch of hundred-dollar bills and several blister-packs of pharmaceuticals.
The mailer was referring to Rep. Will Guzzardi's (D-Chicago) House Bill 3493, which failed to advance out of committee last year on a vote of 8-8. The pharmaceutical industry lobbied hard against the bill and a handful of Democrats on Guzzardi's own committee turned on the chairman's legislation.
Pharma insiders have said ever since House Speaker Michael Madigan appointed members to the chamber's House Prescription Drug Affordability and Accessibility Committee last year that Madigan had helped the industry stack the panel's membership against its own chairman.
Ironically enough, Jones is a co-sponsor of Guzzardi's bill. But he wasn't in committee last Wednesday when the committee took up the bill again, with similar results as last year. Numerous sources on both sides say that Jones refused to allow himself to be replaced on the committee with a substitute. The bill stalled for lack of enough votes to move it to the floor.
Proponents of the legislation point to a January poll of 1,000 Illinoisans which found that high percentages of people are worried about the affordability of prescription drugs, including 52% of folks with employer-based health insurance and 73% of those on Medicaid. According to the poll, 28% of respondents said they had not filled a prescription, cut the pills in half or skipped doses because of cost concerns. And 86% supported the creation of a government board to "examine the evidence and establish acceptable costs for the drug."
The pharmaceutical industry has pulled out all stops against Guzzardi's bill, and its lobbyists have so far managed to stop it in its tracks. Some claim that Guzzardi has refused to listen to their concerns, even though the sponsor filed a clarifying amendment last month. A couple of Democrats said in committee last week that they likely couldn't vote for the bill on the floor in its current form.
In other words, despite all the machinations against his bill, Guzzardi appears to have some work to do. Jones didn't respond to my request for comment, but the day after I told my newsletter subscribers about his no-show, Jones emailed my bookkeeper to inform her that he would not be renewing his Capitol Fax newsletter subscription, which was set to expire next month. "When capitol fax stops being a paid whore for personal pac and anyone who pays you money, I will reconsider," he wrote.
Personal PAC is a pro-choice group that is spending big money against Jones because he didn't vote for the Reproductive Health Act last year. Personal PAC is, like Jones, a newsletter subscriber.
However, the Pharmaceutical Research and Manufacturers of America, which hotly opposed Guzzardi's bill and presumably approved of Jones taking a walk on the roll call, is currently an advertiser on my website, CapitolFax.com. Personal PAC is not an advertiser.
Jones reported spending $170,000 during the second half of 2019, with a lot of that going to campaign workers. He ended the year with a little over $7,000 in the bank, but has raised about $78K so far this year. House Speaker Michael Madigan's political operation has paid for a staffer and some mail in the past month.
Most of Tillman's $77K raised this year has come from Personal PAC's in-kind contributions. The group has so far reported spending almost $49K, including a mailer.
But Jones has the support of Thornton Township Supervisor Frank Zuccarelli's vaunted "Z-Team," which has a ton of experienced and capable precinct workers. That support generally translates into victory.
Jones should be fine, but he's obviously rattled.